Author:
Yasothkumar D.,Ramalingam K.,Ramani P.
Abstract
To the Editor,
Head and neck squamous cell carcinoma (HN- SCC) accounts for about 600,000 new cases globally every year and stands the sixth most common cancer, arising from the squamous epithelium. It is localized in the head and neck area involving oral cavity, pharynx, and larynx. Despite the rigorous therapy, the 5-year overall survival remains poor in HNSCC and has not changed appreciably in the last 30 years. The majority of patients develop resistance to chemotherapeutic agents, and cancer progression occurs. Cetuximab, which targets the epidermal growth factor receptor, and pembrolizumab, an anti-programmed-death ligand 1 antibody, are among few FDA-approved medications. Current therapies are poor and cause severe long-term toxicity, which has a long-term impact on the quality of life [1].......
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Reference11 articles.
1. Bhushan B. Head and Neck Cancer: A Comprehensive Review of Head and Neck Squamous Cell Carcinoma. 2019. 155 p. ISBN 13: 9781076302557
2. Castilho RM, Squarize CH, Almeida LO. Epigenetic modifications and head and neck cancer: implications for tumor progression and resistance to therapy. Int J Mol Sci. 2017;18(7):1506. https://doi.org/10.3390/ijms18071506
3. Lim Y, Sun CX, Tran P, Punyadeera C. Salivary epigenetic biomarkers in head and neck squamous cell carcinomas. Biomark Med. 2016;10(3):301-313. https://doi.org/10.2217/bmm.16.2
4. Arantes LMRB, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM. Methylation as a biomarker for head and neck cancer. Oral Oncol. 2014;50(6):587-592. https://doi.org/10.1016/j.oraloncology.2014.02.015
5. Badawi AM. Important Facts about Cancer Prevention. Trafford Publisher, 2012. 192 p. ISBN 13: 9781466953598